ehc-20220427

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 27, 2022

Encompass Health Corporation

(Exact name of Registrant as specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)


001-10315			63-0860407
(Commission File Number)			(IRS Employer Identification No.)

9001 Liberty Parkway, Birmingham, Alabama 35242

(Address of Principal Executive Offices, Including Zip Code)

(205) 967-7116

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	EHC	New York Stock Exchange

The information contained herein is being furnished pursuant to Item 2.02 of Form 8‑K, “Results of Operations and Financial Condition,” and Item 7.01 of Form 8-K, “Regulation FD Disclosure.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 2.02. Results of Operations and Financial Condition.

On April 27, 2022, Encompass Health Corporation (“Encompass Health” or the “Company”) issued a press release reporting the financial results of the Company for the three months ended March 31, 2022. A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.

The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on hospitals open throughout both the full current and prior periods presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations.

ITEM 7.01. Regulation FD Disclosure.

See Item 2.02, “Results of Operations and Financial Condition,” above.

In addition, a copy of the supplemental information which will be discussed during the Company’s earnings call at 10:00 a.m. Eastern Time on Thursday, April 28, 2022 is attached to this report as Exhibit 99.2 and incorporated herein by reference.

Note Regarding Presentation of Non-GAAP Financial Measures

The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”). The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging and equity instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company’s ongoing operating performance. Accordingly, they can complicate comparisons of the Company’s results of operations across periods and comparisons of the Company’s results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States (“GAAP”) as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies. The Company reconciles adjusted earnings per share to earnings per share in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.

The leverage ratio referenced therein is defined as the ratio of consolidated total debt to Adjusted EBITDA for the trailing four quarters. The Company believes its leverage ratio and Adjusted EBITDA are measures of its ability to service its debt and its ability to make capital expenditures. Additionally, the leverage ratio is a standard measurement used by investors to gauge the creditworthiness of an institution. The Company’s credit agreement also includes a maximum leverage ratio financial covenant which allows the Company to deduct up to $300 million of cash on hand from consolidated total debt. The Company reconciles Adjusted EBITDA to net income and to net cash provided by operating activities in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2. Adjusted EBITDA for the Company’s reportable segments is reconciled to net income from continuing operations before income tax expense in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.

The Company uses Adjusted EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company’s credit agreement, which is discussed in more detail in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Liquidity and Capital Resources,” and Note 10, Long-term Debt, to the consolidated financial statements included in its Annual Report on Form 10‑K for the year ended December 31, 2021 (the “2021 Form 10‑K”). These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under the credit agreement—its interest coverage ratio and its leverage ratio—could result in the Company’s lenders requiring the Company to immediately repay all amounts borrowed. If the Company anticipated a potential covenant violation, it would seek relief from its lenders, which would have some cost to the Company, and such relief might be on terms less favorable to those in the Company’s existing credit agreement. In addition, if the Company cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the Company’s assessment of its liquidity.

In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as “Adjusted Consolidated EBITDA,” allows the Company to add back to consolidated net income interest expense, income taxes, and depreciation and amortization and then add back to consolidated net income (1) all unusual or nonrecurring items reducing consolidated net income (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations, (3) non-ordinary course fees, costs and expenses incurred with respect to any litigation or settlement, (4) share-based compensation expense, (5) costs and expenses associated with changes in the fair value of marketable securities, (6) costs and expenses associated with the issuance or prepayment debt and acquisitions, and (7) any restructuring charges not in excess of 20% of Adjusted Consolidated EBITDA. The Company also subtracts from consolidated net income all unusual or nonrecurring items to the extent they increase consolidated net income.

The calculation of Adjusted EBITDA under the credit agreement does not require us to deduct net income attributable to noncontrolling interests or gains on fair value adjustments of hedging and equity instruments, disposal of assets, and development activities. It also does not allow us to add back losses on fair value adjustments of hedging instruments or unusual or nonrecurring cash expenditures in excess of $10 million. These items and amounts, in addition to the items falling within the credit agreement’s “unusual or nonrecurring” classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to, or be indicative of, the Company's ongoing liquidity or operating performance. Accordingly, the Adjusted EBITDA calculation presented here includes adjustments for them.

Adjusted EBITDA is not a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for net income or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements accompanying the 2021 Form 10-K.

The Company also uses adjusted free cash flow as an analytical indicator to assess its performance. Management believes the presentation of adjusted free cash flow provides investors an efficient means by which they can evaluate the Company’s capacity to reduce debt, pursue development activities, and return capital to its common stockholders. The calculation of adjusted free cash flow and a reconciliation of net cash provided by operating activities to adjusted free cash flow are included in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2. This measure is not a defined measure of financial performance under GAAP and should not be considered as an alternative to net cash provided by operating activities. The Company’s definition of adjusted free cash flow is limited and does not represent residual cash flows available for discretionary spending. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of cash flows included in the 2021 Form 10-K and the condensed consolidated statements of cash flows included in the Company's quarterly report on Form 10-Q for the quarterly period ended March 31, 2022 (the “March 2022 Form 10-Q”), when filed, and in the press release attached as Exhibit 99.1 for the GAAP measures of cash flows from operating, investing, and financing activities.

Forward-Looking Statements

The information contained in the press release and supplemental information includes certain estimates, projections, and other forward-looking statements that involve known and unknown risks and relate to, among other things, future events, including the timing and effects, such as the tax-free treatment and the incremental costs, of the spin off and rebranding of the home health and hospice business and its impact on the business model, outlook and guidance, the expected impact of the COVID-19 pandemic on Encompass Health’s business and financial assumptions, the Company’s business strategy, financial plans, dividend strategies or payments, effective income tax rates, plans to repurchase its debt or equity securities, future financial performance, projected business results or model, ability to return value to its shareholders, projected capital expenditures, leverage ratio, acquisition opportunities, and the impact of future legislation or regulation. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “targets,” “potential,” or “continue” or the negative of these terms or other comparable terminology. These estimates, projections, and other forward-looking statements are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual results, and those differences may be material.

There can be no assurance that any estimates, projections, or forward-looking statements will be realized.

All such estimates, projections, and forward-looking statements speak only as of the date hereof. The Company undertakes no duty to publicly update or revise that information.

You are cautioned not to place undue reliance on the estimates, projections, and other forward-looking statements in this report, the press release, and supplemental information as they are based on current expectations and general assumptions and are subject to various risks, uncertainties, and other factors, including those set forth in the attached press release and in the 2021 Form 10‑K, the March 2022 Form 10-Q when filed, and in other documents the Company previously filed with the SEC, many of which are beyond the Company’s control. These factors may cause actual results to differ materially from the views, beliefs, and estimates expressed herein.

ITEM 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number						Description
99.1						Press release of Encompass Health Corporation, dated April 27, 2022.
99.2						Supplemental information provided in connection with the first quarter 202 2 earnings call of Encompass Health Corporation.
104						Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.


ENCOMPASS HEALTH CORPORATION
By:	/S/ DOUGLAS E. COLTHARP
	Name:	Douglas E. Coltharp
	Title:	Executive Vice President and Chief Financial Officer

Dated: April 27, 2022

Exhibit 99.1


Media Contact			April 27, 2022
Casey Winger, 205 447-6410
[email protected]

Investor Relations Contact
Mark Miller, 205 970-5860
[email protected]

Encompass Health reports results for first quarter 2022

BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE: EHC), a national leader in integrated healthcare, offering facility-based and home-based patient care through its network of inpatient rehabilitation hospitals and home health and hospice agencies, today reported its results of operations for the first quarter ended March 31, 2022.

“Our first quarter results are further evidence of the strong demand for the services we provide,” said President and Chief Executive Officer of Encompass Health Mark Tarr. “Our hospital and home care teams continue to provide high quality, compassionate care to patients in need of our services. While we continue to face near-term staffing challenges, we remain confident in the long-term prospects for our businesses.”

Consolidated results


					Growth
	Q1 2022		Q1 2021		Dollars		Percent
	(In Millions, Except Per Share Data)
Net operating revenues	$	1,333.6	$	1,230.4	$	103.2	8.4	%
Income from continuing operations attributable to Encompass Health per diluted share	0.87		1.07		(0.20)		(18.7)	%
Adjusted earnings per share	0.97		1.05		(0.08)		(7.6)	%
Cash flows provided by operating activities	218.9		158.5		60.4		38.1	%
Adjusted EBITDA	245.0		250.8		(5.8)		(2.3)	%
Adjusted free cash flow	165.9		107.4		58.5		54.5	%

Revenue growth in the first quarter of 2022 resulted primarily from volume growth in both segments.

Income from continuing operations attributable to Encompass Health per diluted share in the first quarter of 2022 was impacted by higher costs associated with the strategic alternatives review and higher stock-based compensation.

Cash flows provided by operating activities increased 38.1% in the first quarter of 2022. Adjusted free cash flow increased 54.5%, primarily as a result of improved working capital. Accounts receivable in the first quarter of 2021 were elevated due predominantly to the phase out of the home health request for anticipated payment and inpatient rehabilitation Medicare payment processing delays.

See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.


						1

Inpatient rehabilitation segment results


							Growth
	Q1 2022			Q1 2021			Dollars		Percent
Net operating revenues:	(In Millions)
Inpatient	$	1,036.2		$	942.3		$	93.9	10.0	%
Outpatient and other	23.1			17.6			5.5		31.3	%
Total segment revenue	$	1,059.3		$	959.9		$	99.4	10.4	%

	(Actual Amounts)
Discharges	50,771			47,187			3,584		7.6	%

Same-store discharge growth									3.8	%
Net patient revenue per discharge	$	20,409		$	19,969		$	440	2.2	%
Revenue reserves related to bad debt as a percent of revenue	2.2		%	1.7		%			50 basis points

	(In Millions)
Adjusted EBITDA	$	226.2		$	234.9		$	(8.7)	(3.7)	%

•Revenue – Inpatient revenue growth resulted from increased volumes and pricing. Total discharge growth for the first quarter of 2022 was 7.6% with same-store growth of 3.8%. Revenue reserves related to bad debt as a percent of revenue increased 50 basis points, primarily attributable to a shift in payor mix toward non-Medicare payors.

Growth in net patient revenue per discharge of 2.2% primarily resulted from an increase in reimbursement rates.

The increase in outpatient and other revenue included an increase of $5.8 million in provider tax revenues (partly offset by an increase of approximately $2.7 million in provider tax expense included in other operating expenses).

•Adjusted EBITDA – The 3.7% decrease in Adjusted EBITDA primarily resulted from increased utilization and pricing of agency staffing and sign-on and shift bonuses in order to service the increased volume of patients.


						2

Home health and hospice segment results


					Growth
	Q1 2022		Q1 2021		Dollars		Percent
Net operating revenues:	(In Millions)
Home health	$	224.9	$	219.9	$	5.0	2.3	%
Hospice	49.4		50.6		(1.2)		(2.4)	%
Total segment revenue	$	274.3	$	270.5	$	3.8	1.4	%

Adjusted EBITDA	$	50.1	$	50.8	$	(0.7)	(1.4)	%

Home Health
Starts of care:	(Actual Amounts)
Total admissions	53,309		50,799		2,510		4.9	%
Same-store total admissions growth							0.9	%
Total recertifications	31,787		31,902		(115)		(0.4)	%
Total starts of care	85,096		82,701		2,395		2.9	%

Episodic admissions	38,971		40,215		(1,244)		(3.1)	%
Same-store episodic admissions growth							(7.4)	%
Episodic recertifications	25,808		28,083		(2,275)		(8.1)	%
Total episodic starts of care	64,779		68,298		(3,519)		(5.2)	%

Revenue per episode	$	3,037	$	2,923	$	114	3.9	%

Hospice
Admissions:
Same store	2,830		3,325		(495)		(14.9)	%
New store	416		5		411		12.4	%
Total admissions	3,246		3,330		(84)		(2.5)	%

•Revenue – Home health total admissions increased 4.9% and same-store total admissions increased 0.9%.

Home health revenue per episode increased 3.9%, driven primarily by an increase in Medicare reimbursement rates.

Hospice admissions decreased 2.5%, primarily attributable to capacity constraints.

•Adjusted EBITDA - The 1.4% decrease in Adjusted EBITDA resulted primarily from increased costs of service due to higher labor costs.


						3

General and administrative expenses


	Q1 2022		% of Consolidated Revenue	Q1 2021		% of Consolidated Revenue
	(In Millions)
General and administrative expenses, excluding stock-based compensation	$	31.3	2.3%	$	34.9	2.8%

General and administrative expenses decreased as a percent of consolidated revenue due to improved operating leverage and a decline in fair value adjustments on the Company’s nonqualified 401(k) plan (offset with “Other Income” in the inpatient rehabilitation segment).

General and administrative expenses in the above table exclude $9.6 million in costs associated with the strategic alternatives review of the Company’s home health and hospice business for the first quarter of 2022.

Spin off of the home health and hospice business

The Company expects the spin off of its home health and hospice business to form an independent, publicly traded company (the “HH&H Business”) to be effectuated on July 1, 2022, subject to customary conditions, including the effectiveness of a Form 10 registration statement, regulatory approvals and receipt of a favorable IRS private letter ruling. Additional information regarding the spin off is provided in the supplemental slides accompanying this release.

2022 guidance

The Company is reaffirming its guidance for full-year 2022.


			2022 Guidance Ranges
			(In Millions, Except Per Share Data)
Net operating revenues			$5,380 to $5,500
Adjusted EBITDA			$1,015 to $1,065
Adjusted earnings per share from continuing operations attributable to Encompass Health			$3.83 to $4.19

The Company’s 2022 consolidated guidance assumes the continuation of the current structure of the business for 2022. Guidance is not inclusive of any costs incurred in 2022 related to the preparations for the planned spin off of Enhabit Home Health & Hospice including rebranding, professional fees, or personnel additions specifically required for an independent public company.

The Company intends to provide 2022 guidance for Encompass Health and Enhabit on a separated basis in the first half of June 2022.

For additional considerations regarding the Company’s 2022 guidance ranges, see the supplemental information posted on the Company’s website at http://investor.encompasshealth.com. See also the “Other information” section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.

Earnings conference call and webcast

The Company will host an investor conference call at 10:00 a.m. Eastern Time on Thursday, April 28, 2022 to discuss its results for the first quarter of 2022. For reference during the call, the Company will post certain supplemental information at http://investor.encompasshealth.com.

The conference call may be accessed by dialing 866 342-8591 and giving the pass code EHCQ122. International callers should dial 203 518-9713 and give the same pass code. Please call approximately ten


						4

minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at http://investor.encompasshealth.com by clicking on an available link.

About Encompass Health

As a national leader in integrated healthcare services, Encompass Health (NYSE: EHC) offers both facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies. With a national footprint that includes 147 hospitals and 252 home health locations and 99 hospice locations in 42 states and Puerto Rico, the Company provides high-quality, cost-effective integrated healthcare. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.

Other information

The information in this press release is summarized and should be read in conjunction with the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the “March 2022 Form 10-Q”), when filed, as well as the Company’s Current Report on Form 8-K filed on April 27, 2022 (the “Q1 Earnings Form 8-K”), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at http://investor.encompasshealth.com for reference during its April 28, 2022 earnings call.

The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q1 Earnings Form 8-K. Readers are encouraged to review the “Note Regarding Presentation of Non-GAAP Financial Measures” included in the Q1 Earnings Form 8-K which provides further explanation and disclosure regarding the Company’s use of these non-GAAP financial measures.

Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company’s results computed in accordance with GAAP.

However, the following reasonably estimable GAAP measures for 2022 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted:

•Interest expense and amortization of debt discounts and fees - estimate of $160 million to $170 million

•Amortization of debt-related items - approximately $10 million

The Q1 Earnings Form 8-K and, when filed, the March 2022 Form 10-Q can be found on the Company’s website at http://investor.encompasshealth.com and the SEC's website at www.sec.gov.


						5

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)


	Three Months Ended March 31,
	2022		2021
	(In Millions, Except Per Share Data)
Net operating revenues	$	1,333.6	$	1,230.4
Operating expenses:
Salaries and benefits	776.0		687.2
Other operating expenses	182.1		162.3
Occupancy costs	20.9		20.2
Supplies	56.1		51.9
General and administrative expenses	48.4		38.6
Depreciation and amortization	66.2		62.5


Total operating expenses	1,149.7		1,022.7
Loss on early extinguishment of debt	0.3		—
Interest expense and amortization of debt discounts and fees	39.6		42.8
Other expense (income)	3.6		(1.4)
Equity in net income of nonconsolidated affiliates	(0.9)		(1.0)
Income from continuing operations before income tax expense	141.3		167.3
Provision for income tax expense	31.2		34.5
Income from continuing operations	110.1		132.8
Loss from discontinued operations, net of tax	—		—
Net and comprehensive income	110.1		132.8
Less: Net and comprehensive income attributable to noncontrolling interests	(22.6)		(25.5)
Net and comprehensive income attributable to Encompass Health	$	87.5	$	107.3



Weighted average common shares outstanding:
Basic	99.2		99.0
Diluted	100.2		100.2
Earnings per common share:
Basic earnings per share attributable to Encompass Health common shareholders:
Continuing operations	$	0.88	$	1.08
Discontinued operations	—		—
Net income	$	0.88	$	1.08
Diluted earnings per share attributable to Encompass Health common shareholders:
Continuing operations	$	0.87	$	1.07
Discontinued operations	—		—
Net income	$	0.87	$	1.07

Amounts attributable to Encompass Health:
Income from continuing operations	$	87.5	$	107.3
Loss from discontinued operations, net of tax	—		—
Net income attributable to Encompass Health	$	87.5	$	107.3


						6

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)


	March 31, 2022		December 31, 2021
	(In Millions)
Assets
Current assets:
Cash and cash equivalents	$	94.2	$	54.8
Restricted cash	61.0		65.1
Accounts receivable	683.5		680.3
Other current assets	111.0		121.2
Total current assets	949.7		921.4
Property and equipment, net	2,667.1		2,601.6
Operating lease right-of-use assets	236.8		242.0
Goodwill	2,456.5		2,427.9
Intangible assets, net	410.6		417.5

Other long-term assets	223.3		254.5
Total assets	$	6,944.0	$	6,864.9
Liabilities and Shareholders’ Equity
Current liabilities:
Current portion of long-term debt	$	42.8	$	42.8
Current operating lease liabilities	38.4		38.4
Accounts payable	147.3		137.6


Accrued expenses and other current liabilities	526.0		530.0
Total current liabilities	754.5		748.8
Long-term debt, net of current portion	3,221.3		3,243.9
Long-term operating lease liabilities	208.3		213.1

Deferred income tax liabilities	89.7		86.7
Other long-term liabilities	178.6		173.2
	4,452.4		4,465.7
Commitments and contingencies

Redeemable noncontrolling interests	43.2		42.2
Shareholders’ equity:
Encompass Health shareholders’ equity	1,973.5		1,911.3
Noncontrolling interests	474.9		445.7
Total shareholders’ equity	2,448.4		2,357.0
Total liabilities and shareholders’ equity	$	6,944.0	$	6,864.9


						7

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Three Months Ended March 31,
	2022		2021
	(In Millions)
Cash flows from operating activities:
Net income	$	110.1	$	132.8



Depreciation and amortization	66.2		62.5




Stock-based compensation	7.5		2.8
Deferred tax expense	2.0		8.7

Other, net	7.9		2.0
Changes in assets and liabilities, net of acquisitions —
Accounts receivable	7.3		(55.1)
Other assets	12.0		1.3

Accrued payroll	5.6		5.7

Other liabilities	0.4		(2.2)

Net cash used in operating activities of discontinued operations	(0.1)		—
Total adjustments	108.8		25.7
Net cash provided by operating activities	218.9		158.5
Cash flows from investing activities:

Purchases of property and equipment	(115.2)		(98.8)






Other, net	(7.9)		3.2

Net cash used in investing activities	(123.1)		(95.6)





Cash flows from financing activities:


Principal payments on debt, including pre-payments	(103.9)		(3.6)

Borrowings on revolving credit facility	130.0		—
Payments on revolving credit facility	(25.0)		—

Debt amendment costs	(20.0)		—

Taxes paid on behalf of employees for shares withheld	(7.6)		(15.6)


Contributions from noncontrolling interests of consolidated affiliates	21.4		4.5
Dividends paid on common stock	(28.5)		(29.1)
Distributions paid to noncontrolling interests of consolidated affiliates	(21.3)		(27.8)
Other, net	(6.0)		(5.9)
Net cash used in financing activities	(60.9)		(77.5)
Increase (decrease) in cash, cash equivalents, and restricted cash	34.9		(14.6)
Cash, cash equivalents. and restricted cash at beginning of period	120.3		310.9
Cash, cash equivalents, and restricted cash at end of period	$	155.2	$	296.3

Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents at beginning of period	$	54.8	$	224.0
Restricted cash at beginning of period	65.1		65.4
Restricted cash included in other long-term assets at beginning of period	0.4		21.5
Cash, cash equivalents, and restricted cash at beginning of period	$	120.3	$	310.9

Cash and cash equivalents at end of period	$	94.2	$	223.9
Restricted cash at end of period	61.0		62.2
Restricted cash included in other long-term assets at end of period	—		10.2
Cash, cash equivalents, and restricted cash at end of period	$	155.2	$	296.3


						8

Encompass Health Corporation and Subsidiaries

Supplemental Information

Earnings Per Share


	Three Months Ended March 31,
	2022		2021
	(In Millions, Except Per Share Data)
Adjusted EBITDA	$	245.0	$	250.8
Depreciation and amortization	(66.2)		(62.5)
Interest expense and amortization of debt discounts and fees	(39.6)		(42.8)
Stock-based compensation	(7.5)		(2.8)
(Loss) gain on disposal or impairment of assets	(0.6)		0.1
	131.1		142.8
Items not indicative of ongoing operating performance:

Loss on early extinguishment of debt	(0.3)		—
Costs associated with the strategic alternatives review	(9.6)		(0.9)



Change in fair market value of equity securities	(2.5)		(0.1)



Pre-tax income	118.7		141.8
Income tax expense	(31.2)		(34.5)
Income from continuing operations (1)	$	87.5	$	107.3

Basic shares	99.2		99.0
Diluted shares	100.2		100.2

Basic earnings per share (1)	$	0.88	$	1.08
Diluted earnings per share (1)	$	0.87	$	1.07

(1)Income from continuing operations attributable to Encompass Health


						9

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share


	Q1
	2022		2021

Earnings per share, as reported	$	0.87	$	1.07
Adjustments, net of tax:




Costs associated with the strategic alternatives review	0.07		0.01

Income tax adjustments	—		(0.03)


Change in fair market value of equity securities	0.02		—


Adjusted earnings per share*	$	0.97	$	1.05

* Adjusted EPS may not sum due to rounding.


						10

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share


	For the Three Months Ended March 31, 2022
			Adjustments
	As Reported		Loss on Early Extinguishment of Debt		Income Tax Adjustments		Costs Associated with the Strategic Alternatives Review		Change in Fair Market Value of Equity Securities		As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	245.0	$	—	$	—	$	—	$	—	$	245.0
Depreciation and amortization	(66.2)		—		—		—		—		(66.2)
Interest expense and amortization of debt discounts and fees	(39.6)		—		—		—		—		(39.6)
Stock-based compensation	(7.5)		—		—		—		—		(7.5)
Loss on disposal or impairment of assets	(0.6)		—		—		—		—		(0.6)

Loss on early extinguishment of debt	(0.3)		0.3		—		—		—		—
Costs associated with the strategic alternatives review	(9.6)		—		—		9.6		—		—



Change in fair market value of equity securities	(2.5)		—		—		—		2.5		—



Income from continuing operations before income tax expense	118.7		0.3		—		9.6		2.5		131.1
Provision for income tax expense	(31.2)		(0.1)		0.2		(2.5)		(0.6)		(34.2)
Income from continuing operations attributable to Encompass Health	$	87.5	$	0.2	$	0.2	$	7.1	$	1.9	$	96.9



Diluted earnings per share from continuing operations**	$	0.87	$	—	$	—	$	0.07	$	0.02	$	0.97
Diluted shares used in calculation	100.2

* Reconciliation to GAAP provided on page 13

** Adjusted EPS may not sum across due to rounding.


						11

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share


	For the Three Months Ended March 31, 2021
			Adjustments
	As Reported		Income Tax Adjustments		Costs Associated with the Strategic Alternatives Review		Change in Fair Market Value of Equity Securities		As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	250.8	$	—	$	—	$	—	$	250.8
Depreciation and amortization	(62.5)		—		—		—		(62.5)
Interest expense and amortization of debt discounts and fees	(42.8)		—		—		—		(42.8)
Stock-based compensation	(2.8)		—		—		—		(2.8)
Gain on disposal or impairment of assets	0.1		—		—		—		0.1


Costs associated with the strategic alternatives review	(0.9)		—		0.9		—



Change in fair market value of equity securities	(0.1)		—		—		0.1		—



Income from continuing operations before income tax expense	141.8		—		0.9		0.1		142.8
Provision for income tax expense	(34.5)		(3.3)		(0.2)		—		(38.0)
Income from continuing operations attributable to Encompass Health	$	107.3	$	(3.3)	$	0.7	$	0.1	$	104.8



Diluted earnings per share from continuing operations**	$	1.07	$	(0.03)	$	0.01	$	—	$	1.05
Diluted shares used in calculation	100.2

* Reconciliation to GAAP provided on page 13

** Adjusted EPS may not sum across due to rounding.


						12

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Income to Adjusted EBITDA


	Three Months Ended March 31,
	2022		2021
	(In Millions)
Net income	$	110.1	$	132.8

Net income attributable to noncontrolling interests	(22.6)		(25.5)
Provision for income tax expense	31.2		34.5
Interest expense and amortization of debt discounts and fees	39.6		42.8
Depreciation and amortization	66.2		62.5


Loss on early extinguishment of debt	0.3		—
Loss (gain) on disposal or impairment of assets	0.6		(0.1)
Stock-based compensation	7.5		2.8
Costs associated with the strategic alternatives review	9.6		0.9




Change in fair market value of equity securities	2.5		0.1


Adjusted EBITDA	$	245.0	$	250.8

Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations

Before Income Tax Expense


	Three Months Ended March 31,
	2022		2021
	(In Millions)
Total segment Adjusted EBITDA	$	276.3	$	285.7
General and administrative expenses	(48.4)		(38.6)
Depreciation and amortization	(66.2)		(62.5)
(Loss) gain on disposal or impairment of assets	(0.6)		0.1


Loss on early extinguishment of debt	(0.3)		—
Interest expense and amortization of debt discounts and fees	(39.6)		(42.8)
Net income attributable to noncontrolling interests	22.6		25.5

Change in fair market value of equity securities	(2.5)		(0.1)



Income from continuing operations before income tax expense	$	141.3	$	167.3


						13

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA


	Three Months Ended March 31,

	2022		2021
	(In Millions)
Net cash provided by operating activities	$	218.9	$	158.5

Interest expense and amortization of debt discounts and fees	39.6		42.8
Equity in net income of nonconsolidated affiliates	0.9		1.0
Net income attributable to noncontrolling interests in continuing operations	(22.6)		(25.5)
Amortization of debt-related items	(2.3)		(2.0)
Distributions from nonconsolidated affiliates	(1.0)		(1.0)
Current portion of income tax expense	29.2		25.8
Change in assets and liabilities	(25.3)		50.3
Cash used in operating activities of discontinued operations	0.1		—
Costs associated with the strategic alternatives review	9.6		0.9





Change in fair market value of equity securities	2.5		0.1
Other	(4.6)		(0.1)
Adjusted EBITDA	$	245.0	$	250.8


						14

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow


	Three Months Ended March 31,

	2022		2021
	(In Millions)
Net cash provided by operating activities	$	218.9	$	158.5
Impact of discontinued operations	0.1		—
Net cash provided by operating activities of continuing operations	219.0		158.5
Capital expenditures for maintenance	(34.5)		(23.3)
Distributions paid to noncontrolling interests of consolidated affiliates	(21.3)		(27.8)
Items not indicative of ongoing operating performance:


Transaction costs and related assumed liabilities	2.7		—

Adjusted free cash flow	$	165.9	$	107.4

For the three months ended March 31, 2022, net cash used in investing activities was $123.1 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended March 31, 2022 was $60.9 million and resulted primarily from net debt repayments and amendment costs, cash dividends paid on common stock and distributions to noncontrolling interests of consolidated affiliates.

For the three months ended March 31, 2021, net cash used in investing activities was $95.6 million and primarily resulted from capital expenditures. Net cash used in financing activities during the three months ended March 31, 2021 was $77.5 million and primarily resulted from cash dividends paid on common stock, distributions to noncontrolling interests of consolidated affiliates and taxes paid of behalf of employees for shares withheld under stock compensation arrangements.


						15

Encompass Health Corporation and Subsidiaries

Forward-Looking Statements

Statements contained in this press release and the supplemental information which are not historical facts, such as those relating to the timing and effects, such as the tax-free treatment and the incremental costs, of the spin-off and rebranding of the home health and hospice business and its impact on the business model, outlook and guidance, the nature of the COVID-19 pandemic and its impact on Encompass Health's business and financial assumptions, legislative and regulatory developments, financial guidance, balance sheet and cash flow plans, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information, involve a number of risks and uncertainties, and relate to, among other things, future events, Encompass Health's plan to repurchase its debt or equity securities, dividend strategies, effective income tax rates, its business strategy, its financial plans, its future financial performance, its projected business results or model, its ability to return value to shareholders, its projected capital expenditures, its leverage ratio, its acquisition opportunities, and the impact of future legislation or regulation. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, the possibility that the Company may not be able to realize higher values for its home health and hospice business through strategic transactions; the possibility that the Company may decide not to undertake a transaction following the review of strategic alternatives or that it is not able to consummate any proposed transactions resulting from the review due to, among other things, market, regulatory and other factors; the potential for disruption to the Company's business resulting from the review of strategic alternatives or the undertaking of any transactions following the review; the continued spread of COVID-19, including the speed, depth, geographic reach and duration of the spread, which could decrease our patient volumes and revenues and lead to staffing and supply shortages and associated cost increases; actions to be taken by the Company in response to the pandemic; the legal, regulatory and administrative developments that occur at the federal, state and local levels; the Company's infectious disease prevention and control efforts; the demand for the Company's services, including based on any downturns in the economy, consumer confidence, or the capital markets and unemployment among family members; the price of Encompass Health's common stock as it affects the Company's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including any matters related to yet undiscovered issues, if any, in acquired operations; Encompass Health's ability to attract and retain key management personnel; any adverse effects on Encompass Health's stock price resulting from the integration of acquired operations; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's or its vendors' information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability as well as unforeseen issues, if any, related to integration of acquired systems; the ability to successfully integrate acquired operations, including realization of anticipated tax benefits, revenues, and cost savings, minimizing the negative impact on margins arising from the changes in staffing and other operating practices, and avoidance of unforeseen exposure to liabilities; Encompass Health's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; increases in Medicare audit activity, including increased use of sampling and extrapolation, resulting in additional unpaid reimbursement claims and an increase in the backlog of appealed claims denials; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction (such as the Patient-Driven Groupings Model for home health) and Encompass Health's ability to adapt operations to those changes; competitive pressures in the healthcare industry and Encompass Health's response thereto; Encompass Health's ability to obtain and


						16

Encompass Health Corporation and Subsidiaries

Forward-Looking Statements

retain favorable arrangements with third-party payors; Encompass Health's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in Encompass Health's ability to recover improperly denied claims through the administrative appeals process on a timely basis; Encompass Health's ability to adapt to changes in the healthcare delivery system, including value-based purchasing and involvement in coordinated care initiatives or programs that may arise with its referral sources; Encompass Health's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages, which may be worsened by the pandemic, and the impact on Encompass Health's labor expenses from potential union activity and staffing shortages; general conditions in the economy and capital markets, including any instability or uncertainty related to armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; the increase in the costs of defending and insuring against alleged professional liability claims, including claims associated with patient and employee exposures to COVID-19, and Encompass Health's ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10‑K for the year ended December 31, 2021 and Form 10-Q for the quarter ended March 31, 2022, when filed.


						17

Earnings Call April 28, 2022 Supplemental information 2022 First Quarter

Encompass Health 2 The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect Encompass Health’s current outlook, views and plans with respect to future events, including the timing and effects, such as the tax-free treatment and the incremental costs, of the spin off and rebranding of the home health and hospice business and its impact on the business model, outlook and guidance, the COVID-19 pandemic and its effects, legislative and regulatory developments, strategy, capital expenditures, acquisition and other development activities, cyber security, dividend strategies, repurchases of securities, effective tax rates, financial performance, financial assumptions, business model, balance sheet and cash flow plans, market share, and shareholder value-enhancing transactions. These estimates, projections and other forward-looking information are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material. There can be no assurance any estimates, projections or forward-looking information will be realized. All such estimates, projections and forward-looking information speak only as of the date hereof. Encompass Health undertakes no duty to publicly update or revise the information contained herein. You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the earnings release attached as Exhibit 99.1 to the Company’s Form 8-K dated April 27, 2022 (the “Q1 Earnings Release Form 8-K”), the Form 10-K for the year ended December 31, 2021, the Form 10-Q for the quarter ended March 31, 2022, when filed, and in other documents Encompass Health previously filed with the SEC, many of which are beyond Encompass Health’s control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein. Note regarding presentation of non-GAAP financial measures The following presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, leverage ratios, adjusted earnings per share, and adjusted free cash flow. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. The Q1 Earnings Release Form 8-K, to which the following presentation is attached as Exhibit 99.2, provides further explanation and disclosure regarding Encompass Health’s use of non-GAAP financial measures and should be read in conjunction with this supplemental information. Forward-looking statements

Encompass Health 3 Q1 2022 Key takeaways ...................................................................................................................................................................... 4 Spin off of Enhabit ................................................................................................................................................................................ 5 Q1 2022 Summary ................................................................................................................................................................................. 6 Inpatient rehabilitation segment ...................................................................................................................................................... 7-8 Home health & hospice segment ....................................................................................................................................................... 9-10 Consolidated Adjusted EBITDA .......................................................................................................................................................... 11 Earnings per share ................................................................................................................................................................................ 12-13 Adjusted free cash flow ....................................................................................................................................................................... 14 Guidance and considerations for 2022 ............................................................................................................................................ 15-16 Adjusted free cash flow assumptions ............................................................................................................................................... 17 Uses of free cash flow .......................................................................................................................................................................... 18 2022-2026 Growth targets ................................................................................................................................................................. 19 Appendix Map of locations ..................................................................................................................................................................................... 21 Expansion activity ................................................................................................................................................................................. 22 Clinical collaboration ........................................................................................................................................................................... 23 Pre-payment claims denials - inpatient rehabilitation segment ............................................................................................... 24 Debt maturity profile and schedule ................................................................................................................................................. 25-26 New-store/same-store growth ........................................................................................................................................................... 27-29 Payment sources (percent of revenues) ......................................................................................................................................... 30 Inpatient rehabilitation operational metrics ................................................................................................................................. 31 Home health & hospice operational metrics .................................................................................................................................. 32 Share information ................................................................................................................................................................................. 33 Segment operating results .................................................................................................................................................................. 34-35 Reconciliations to GAAP ...................................................................................................................................................................... 36-42 End notes ................................................................................................................................................................................................ 43-44 Table of contents

Encompass Health 4 Q1 2022 Key takeaways u Revenue growth offset by elevated staffing costs Ÿ Consolidated revenues increased 8.4% Ÿ Strong inpatient rehabilitation discharge growth: 7.6% total; 3.8% same store Ÿ Solid home health admissions growth: 4.9% total; 0.9% same store Ÿ Staffing costs continue to be elevated. ü Inpatient rehabilitation Q1 2022 SWB of 55.5% of revenue vs. Q1 2021 SWB of 52.3% of revenue ü Home health Q1 2022 CPV of $83 vs. Q1 2021 CPV of $77 u Continued capacity additions in both businesses Ÿ Opened three IRF de novos in Q1 2022 (140 beds) and added 29 beds to existing hospitals Ÿ Plan to open an additional six de novo IRFs (additional 270 beds) and add an additional 89 beds to existing hospitals in 2022 Ÿ Opened four home health and hospice locations in Q1 2022 (two of the four were acquired) Ÿ Plan to open an additional eight de novo locations in 2022 u Balance sheet - see debt schedule and maturity profile on pages 25-26 Ÿ Net leverage ratio of 3.1x at quarter end u Strong free cash flow generation - see page 14 Ÿ Q1 Adjusted free cash flow increased 54.5% to $165.9 million u Shareholder and other distributions Ÿ Paid quarterly cash dividend of $0.28 per share in January 2022 Ÿ Declared a $0.28 per share quarterly cash dividend in February 2022 (paid April 2022) u Reaffirming 2022 consolidated Net Operating Revenue, Adjusted EBITDA and Adjusted EPS guidance - see pages 15-16

Encompass Health 5 Spin off of Enhabit u Spin off of Enhabit expected on July 1, 2022 Ÿ The spin off is expected to be tax free to EHC shareholders. (A Private Letter Ruling request has been filed with the IRS.) Ÿ Confidential Form 10 filed in April; public filing expected mid to late May Ÿ We intend to provide 2022 guidance for Encompass Health and Enhabit on a separated basis in the first half of June. u Rebranding update Ÿ The rebranding of branches began, as scheduled, in mid-April and is expected to be largely completed by the effective date of the spin off. u Financial considerations update for the spin off Ÿ Anticipating leverage (Debt to Adjusted EBITDA) at the effective date of approximately 3.0-3.25x at Enhabit and 3.25-3.5x at Encompass. Ÿ Establishing Enhabit as a stand-alone entity is expected to result in $26-$28 million of incremental annualized G&A costs, and a $5-$10 million* reduction in annualized G&A expenses for Encompass Health. Certain administrative services will be provided by Encompass Health to Enhabit on an interim basis following the spin off under a transition services agreement. Ÿ Rebranding expenses for Enhabit are expected to be $5-$8 million in operating expenses and $2-$4 million in capital expenditures. These expenses are expected to be incurred in 2022 and have been revised downward from our previous estimate. *Position within this range is dependent, among other things, on the scope and duration of a transition services agreement.

Encompass Health 6 Q1 2022 Summary Q1 ($ in millions) 2022 2021 % △ Encompass Health Consolidated Net operating revenues $ 1,333.6 $ 1,230.4 8.4 % Adjusted EBITDA $ 245.0 $ 250.8 (2.3) % Adjusted EPS $ 0.97 $ 1.05 (7.6) % Adjusted free cash flow* $ 165.9 $ 107.4 54.5 % Inpatient Rehabilitation Segment Net operating revenues $ 1,059.3 $ 959.9 10.4 % Adjusted EBITDA $ 226.2 $ 234.9 (3.7) % Home Health and Hospice Segment Net operating revenues $ 274.3 $ 270.5 1.4 % Adjusted EBITDA $ 50.1 $ 50.8 (1.4) % *Refer to page 14 for a discussion of year-to-year change. Reconciliations to GAAP provided on pages 36-42

Encompass Health 7 Inpatient rehabilitation segment - revenue Q1 Q1 Favorable/ ($ in millions) 2022 2021 (Unfavorable) Net operating revenues: Inpatient $ 1,036.2 $ 942.3 10.0% Outpatient and other 23.1 17.6 31.3% Total segment revenue $ 1,059.3 $ 959.9 10.4% (Actual Amounts) Discharges 50,771 47,187 7.6% Same-store discharge growth 3.8% Net patient revenue per discharge $ 20,409 $ 19,969 2.2% Revenue reserves related to bad debt as a percent of revenue 2.2 % 1.7 % 50 basis points u Net revenue per discharge growth of 2.2% was driven primarily by an increase in reimbursement rates. u Outpatient and other revenue included an increase of $5.8 million in provider tax revenue ($14.4 million in Q1 2022 vs. $8.6 million in Q1 2021). u Revenue reserves related to bad debt increased 50 bps to 2.2%, primarily due to the impact of the payor mix shift to Medicare Advantage and Managed Care (longer collection times and higher patient payment responsibility).

Encompass Health 8 Inpatient rehabilitation segment - Adjusted EBITDA Q1 % of Revenue Q1 % of Revenue($ in millions) 2022 2021 Net operating revenues $ 1,059.3 $ 959.9 Operating expenses: Salaries and benefits (587.4) 55.5 % (501.9) 52.3 % Other operating expenses(a) (158.3) 14.9 % (140.0) 14.6 % Supplies (49.8) 4.7 % (45.2) 4.7 % Occupancy costs (15.4) 1.5 % (15.1) 1.6 % Hospital operating expenses (223.5) 21.1 % (200.3) 20.9 % Other (expense) income(b) (1.1) 1.5 Equity in nonconsolidated affiliates 0.9 0.8 Noncontrolling interests (22.0) (25.1) Segment Adjusted EBITDA $ 226.2 $ 234.9 Percent change (3.7) % In arriving at Adjusted EBITDA, the following were excluded: (a) Loss on disposal or impairment of assets $ 0.7 $ — (b) Change in fair market value of equity securities $ 2.5 $ 0.1 Reconciliations to GAAP provided on pages 36-42 u Salary and benefits in Q1 2022 included ~$63 million in agency staffing and sign-on and shift bonuses, compared to ~$21 million in Q1 2021. u Other operating expenses included an increase of $2.7 million in provider tax expense ($12.3 million in Q1 2022 vs. $9.6 million in Q1 2021).

Encompass Health 9 Home health and hospice segment - revenue Q1 Q1 Favorable/ ($ in millions) 2022 2021 (Unfavorable) Net operating revenues: Home health revenue $ 224.9 $ 219.9 2.3 % Hospice revenue 49.4 50.6 (2.4) % Total segment revenue $ 274.3 $ 270.5 1.4 % Home Health Starts of care: Total admissions 53,309 50,799 4.9 % Same-store total admissions growth 0.9 % Total recertifications 31,787 31,902 (0.4) % Total starts of care 85,096 82,701 2.9 % Episodic admissions 38,971 40,215 (3.1) % Same-store episodic admissions growth (7.4) % Episodic recertifications 25,808 28,083 (8.1) % Total episodic starts of care 64,779 68,298 (5.2) % Revenue per episode $ 3,037 $ 2,923 3.9 % Hospice Admissions: Same store 2,830 3,325 (14.9) % New store 416 5 12.4 % Total admissions 3,246 3,330 (2.5) % u Home health revenue increased 2.3% in Q1 2022, resulting from 4.9% total admissions growth offset by the pricing impact of payor mix shift. u Hospice admissions declined 2.5% in Q1 2022, primarily attributable to capacity constraints.

Encompass Health 10 Q1 % of Revenue Q1 % of Revenue($ in millions) 2022 2021 Net operating revenues $ 274.3 $ 270.5 Cost of services (124.4) 45.4 % (118.1) 43.7 % Support and overhead costs (99.2) 36.2 % (101.4) 37.5 % Operating expenses(a) (223.6) 81.5 % (219.5) 81.1 % Equity in net income of nonconsolidated affiliates — 0.2 Noncontrolling interests (0.6) (0.4) Segment Adjusted EBITDA $ 50.1 $ 50.8 Percent change (1.4) % In arriving at Adjusted EBITDA, the following were excluded: (a) Gain on disposal or impairment of assets $ (0.1) $ (0.1) Home health and hospice segment - Adjusted EBITDA Reconciliations to GAAP provided on pages 36-42 u Cost of services increased in Q1 2022 primarily due to higher labor costs. Ÿ Home health cost per visit increased 7.8%. Ÿ Hospice cost per day increased 6.4%.

Encompass Health 11 Consolidated Adjusted EBITDA ($ in millions) Q1 2022 % of Consolidated Revenue Q1 2021 % of Consolidated Revenue Inpatient rehabilitation segment Adjusted EBITDA $ 226.2 $ 234.9 Home health and hospice segment Adjusted EBITDA 50.1 50.8 General and administrative expenses* (31.3) 2.3% (34.9) 2.8% Consolidated Adjusted EBITDA $ 245.0 $ 250.8 Percentage change (2.3) % Reconciliations to GAAP provided on pages 36-42 Consolidated Adjusted EBITDA for the quarter of $245.0 million u General and administrative expenses decreased as a percent of consolidated revenue due to improved operating leverage and a decline in fair value adjustments on the Company’s nonqualified 401(k) plan (offset within ‘Other Income’ in the IRF segment). * General and administrative expenses in the above table exclude stock compensation of $7.5 million and $2.8 million for Q1 2022 and Q1 2021, respectively, as well as $9.6 million and $0.9 million in costs associated with the strategic alternatives review of our home health and hospice business for Q1 2022 and Q1 2021, respectively.

Encompass Health 12 Earnings per share - as reported Q1 ($ in millions, except per share data) 2022 2021 Adjusted EBITDA $ 245.0 $ 250.8 Depreciation and amortization (66.2) (62.5) Interest expense and amortization of debt discounts and fees (39.6) (42.8) Stock-based compensation (7.5) (2.8) (Loss) gain on disposal or impairment of assets (0.6) 0.1 131.1 142.8 Items not indicative of ongoing operating performance: Loss on early extinguishment of debt(1) (0.3) — Costs associated with the strategic alternatives review (9.6) (0.9) Change in fair market value of equity securities (2.5) (0.1) Pre-tax income 118.7 141.8 Income tax expense (31.2) (34.5) Income from continuing operations* $ 87.5 $ 107.3 Diluted shares (see page 33) 100.2 100.2 Diluted earnings per share* $ 0.87 $ 1.07 u EPS in Q1 2022 was impacted by higher costs associated with the strategic alternatives review and higher stock-based compensation. * Earnings per share are determined using income from continuing operations attributable to Encompass Health. Refer to pages 43-44 for end notes.

Encompass Health 13 Adjusted earnings per share(2) * Adjusted EPS may not sum due to rounding. See complete calculations of adjusted earnings per share on pages 41-42. Refer to pages 43-44 for end notes. Q1 2022 2021 Earnings per share, as reported $ 0.87 $ 1.07 Adjustments, net of tax: Costs associated with the strategic alternatives review 0.07 0.01 Income tax adjustments — (0.03) Change in fair market value of equity securities 0.02 — Adjusted earnings per share* $ 0.97 $ 1.05 u Adjusted earnings per share removes from the GAAP earnings per share calculation the impact of items the Company believes are non-indicative of its ongoing operating performance.

Encompass Health 14 107.4 (5.8) 72.7 3.5 (0.7) (11.2) 165.9 Adjusted Free Cash Flow 3 Mos. 2021 Adjusted EBITDA Working capital and other Cash interest payments Cash tax payments, net of refunds Maintenance capital expenditures Adjusted Free Cash Flow 3 Mos. 2022 2022 YTD Adjusted free cash flow(3) Reconciliations to GAAP provided on pages 36-42 Refer to pages 43-44 for end notes. u Adjusted free cash flow growth in the first three months of 2022 was predominantly attributable to improved working capital. Ÿ Accounts receivable in Q1 2021 was elevated due to the phase out of the home health request for anticipated payment (“RAP”) and IRF Medicare payment processing delays. ($ in millions)

Encompass Health 15 2022 Guidance - Reaffirmed The Company's 2022 guidance assumes the continuation of the current structure of the business for 2022. Refer to pages 43-44 for end notes. 2021 Actuals 2022 Guidance* ($ in millions, except per share data) Net Operating Revenue $5,122 $5,380 to $5,500 Adjusted EBITDA (4) $1,028 $1,015 to $1,065 Adjusted earnings per share from continuing operations attributable to Encompass Health (2) $4.23 $3.83 to $4.19 *Not inclusive of any costs incurred in 2022 related to the preparations for the planned spin off of Enhabit Home Health & Hospice including rebranding, professional fees, or personnel additions specifically required for an independent public company.

Encompass Health 16 2022 Guidance considerations Inpatient Rehabilitation u Estimated increase of 1.9% in Medicare pricing prior to resumption of sequestration u Revenue reserves related to bad debt of 1.8% to 2.0% of net operating revenues u Salaries and benefits per FTE (inclusive of agency staffing costs, sign-on and shift bonuses) increase of 4% to 5% u Pre-opening and new-store ramp-up costs of $10 million to $13 million Home Health and Hospice u Estimated increase of 3.4% in Medicare pricing for home health prior to resumption of sequestration u Estimated increase of 2.0% in Medicare pricing for hospice prior to resumption of sequestration u Cost per visit increase of 4% to 5% for home health u Cost per patient day increase of 3% to 4% for hospice u Incremental investment of $2 million to $3 million for de novo locations Consolidated u Medicare pricing increases will be affected by phased in resumption of sequestration: 1% in Q2, 2% in Q3 and Q4. u Staffing constraints and elevated costs are expected to continue in 2022 with improvement skewed toward the second half of the year. u Guidance is not inclusive of any costs incurred in 2022 related to the preparations for the planned spin off of Enhabit including rebranding, professional fees, or personnel additions specifically required for an independent public company. Changes from previous guidance considerations are underlined.

Encompass Health 17 Adjusted free cash flow(3) assumptions Certain cash flow items ($ in millions) 3 Months 2022 Actuals 2021 Actuals 2022 Assumptions Cash interest payments (net of amortization of debt discounts and fees) $37.3 $156.8 $150 to $160 Cash payments for income taxes, net of refunds $— $129.6 $80 to $100 Working capital and other $7.3 $104.0 $80 to $100 Maintenance CAPEX $34.5 $138.8 $200 to $250 Adjusted free cash flow $165.9 $498.8 $405 to $555 uDecrease due to overpayments from 2021 applied to 2022 uModest decrease in working capital expected due to timing of collections uIncreased maintenance CAPEX related to carryover projects from 2021 due to construction supply chain challenges; additional spending for equipment replacement, and renovations to existing hospitals uCash interest payments expected to be flat due to redemption of 5.125% Senior Notes due 2023 offset by higher revolver borrowings and increases in short term rates in 2022 Reconciliations to GAAP provided on pages 36-42 Refer to pages 43-44 for end notes.

Encompass Health 18 Uses of free cash flow ($ in millions) 3 Months 2022 Actuals 2022 Assumptions 2021 Actuals Growth in core business IRF bed expansions $9.1 $40 to $50 $48.6 New IRFs - De novos 71.0 320 to 340 314.9 - Acquisitions — opportunistic 1.1 - Replacement IRFs and other 5.5 10 to 20 48.9 Home health and hospice acquisitions* — 50 to 100 117.5 $85.6 $420 to $510 $531.0 Debt reduction Debt redemptions (borrowings), net $22.6 TBD $2.2 Shareholder and other distributions Cash dividends on common stock 28.5 TBD 112.4 Common stock repurchases — opportunistic — ~$198 million authorization remaining as of March 31, 2022(5) See the debt schedule on page 26. Refer to pages 43-44 for end notes. Quarterly cash dividend currently set at $0.28 per common share *Includes approximately $16 million related to an acquisition effective on January 1, 2022 that was paid in 2021.

Encompass Health 19 2022-2026 Growth targets INPATIENT REHABILITATION HOME HEALTH AND HOSPICE 6 to 10 De novos per year 100 to 150 bed additions per year 6% to 8% Discharge CAGR 10% Home Health admissions CAGR 10% to 15% Hospice admissions CAGR $50 million to $100 million Acquisitions per year Strong and sustainable business fundamentals Ÿ Strong demographic tailwinds Ÿ Multi-faceted growth strategies Ÿ Highly fragmented post-acute sectors present acquisition and joint venture opportunities. Ÿ Consistent delivery of high-quality, cost-effective, facility-based and home-based care Ÿ Economies related to scale and market density Ÿ Substantial cash flow generation

Appendix

Encompass Health 21 Portfolio as of 03/31/22 Inpatient rehabilitation hospitals (“IRFs”) Home health locations Hospice locations 23 Future IRFs** 42 States and Puerto Rico ~43,500 employees Inpatient rehabilitation - 03/31/22 147 IRFs (54 are joint ventures) 35 States and Puerto Rico ~32,900 Employees 24 % of licensed beds† 31 % of Medicare patients served† Key statistics - trailing 4 quarters ~201,200 Inpatient discharges ~$4.1 Billion in revenue * Excluding markets that have home health licensure barriers ** Future IRFs - Previously announced under development as of April 27, 2022 † Based on 2019 and 2020 data Encompass Health a leading provider of inpatient rehabilitation and home-based care 96 of EHC’s IRFs have an EHC home health location within the service area.* Largest owner and operator of IRFs 4th Largest provider of Medicare-certified skilled home health services one of the 2022 FORTUNE® “World’s Most Admired Companies” Home health and hospice - 03/31/22 252 Home health locations 99 Hospice locations 34 States ~10,600 Employees Key statistics - trailing 4 quarters ~203,100 Home health total admissions ~13,000 Hospice admissions ~$1.1 Billion in revenue

Encompass Health 22 Inpatient Rehabilitation Facilities Opened or Under Development Expected operations date Joint venture # of New Beds 2022 2023 2024 De novo IRFs: Shiloh, IL Q1 2022 ü 40 — — St. Augustine, FL Q1 2022 40 — — Libertyville, IL Q1 2022 60 — — 1 Lakeland, FL Q2 2022 50 — — 2 Cape Coral, FL Q2 2022 ü 40 — — 3 Jacksonville, FL Q2 2022 50 — — 4 Moline, IL Q3 2022 ü 40 — — 5 Naples, FL Q3 2022 50 — — 6 Grand Forks, ND Q3 2022 ü 40 — — 7 Eau Claire, WI 2023 ü — 36 — 8 Owasso, OK 2023 ü — 40 — 9 Clermont, FL 2023 — 50 — 10 Knoxville, TN 2023 ü — 73 — 11 Bowie, MD 2023 — 60 — 12 Prosper, TX 2023 — 40 — 13 Columbus, GA 2023 ü — 40 — 14 Strongville, OH 2023 — 40 — 15 Fitchburg, WI 2023 — 40 — 16 Louisville, KY 2023 ü — 40 — 17 Kissimmee, FL TBD — — 50 18 Fort Mill, SC TBD — — 39 19 Amarillo, TX TBD — — 40 20 Atlanta, GA TBD ü — — 40 21 Lake Worth, FL TBD — — 50 22 Fort Myers, FL TBD ü — — 60 23 Palm Beach Gardens, FL TBD — — 50 Bed expansions, net* ~100 ~100 ~100 ~510 ~560 ~430 Expansion activity *Net bed expansions in each year may change due to the timing of certain regulatory approvals and/or construction delays. For 2022 through 2024, the currently expected range for bed expansions is 100 to 150. Q1 2022 Expansion activity highlights u Opened 3 inpatient rehabilitation hospitals Ÿ 40-bed IRF in Shiloh, IL Ÿ 40-bed IRF in St. Augustine, FL Ÿ 60-bed IRF in Libertyville, IL u Added 29 beds to existing hospitals u Announced plans to build a 60-bed inpatient rehabilitation hospital in Fort Myers, FL IRF development projects announced and underway Home Health and Hospice Locations # of Locations December 31, 2021 347 Acquisitions 2 Opening of new locations 2 Merging of locations — March 31, 2022 351 23

Encompass Health 23 * Overlap markets have an Encompass Health IRF and an Encompass Health home health location within an approximate 30-mile radius, excluding markets that have home health licensure barriers. Overlap markets are open for 12 months before inclusion in the clinical collaboration rate. The Company continues to improve the patient experience and outcomes through integrated care delivery. Inpatient rehabilitation–home health clinical collaboration (all payors) overlap markets* EHC Home Health Non-EHC Home Health Encompass Health IRF discharges to: Overlap Markets* Clinical Collaboration Rate 17.260 uClinical collaboration objectives: Ÿ Improve patient experience and outcomes Ÿ Reduce total cost of care across a post-acute episode 72 76 81 89 89 95 96 25.4% 29.5% 34.0% 35.6% 33.2% 31.9% 31.6% 2016 2017 2018 2019 2020 2021 YTD 2022 40,637 42,950 41,858 44,479 13,800 17,947 21,547 24,560 25,444 57,761 27,017 uThe clinical collaboration rate has decreased primarily due to Medicare Advantage increasing as a percent of the total patient mix and home health staffing constraints in certain overlap markets. 51,287 6,764 14,663

Encompass Health 24 Pre-payment claims denials - inpatient rehabilitation segment Impact to Income Statement Period New Denials Collections of Previously Denied Claims Revenue Reserve for New Denials Update of Reserve for Prior Denials (In Millions) Q1 2022 $1.1 $(5.6) $0.3 $— Q4 2021 1.4 (8.1) 0.4 — Q3 2021 (0.5) (9.7) — — Q2 2021 0.1 (6.3) — — Q1 2021 (0.2) (5.2) — — Q4 2020 (0.4) (7.2) — 4.5 Q3 2020 (0.6) (6.3) — — Q2 2020 (1.5) (3.5) — — Q1 2020 4.2 (5.0) 1.3 — Q4 2019 3.8 (4.6) 1.1 — Q3 2019 11.3 (6.1) 3.4 — Q2 2019 3.5 (1.7) 1.1 — Impact to Balance Sheet March 31, 2022 Dec. 31, 2021 Dec. 31, 2020 (In Millions) Pre-payment claims denials $ 55.7 $ 69.0 $ 122.8 Recorded reserves (18.7) (25.7) (41.3) from pre-payment claims denials $ 37.0 $ 43.3 $ 81.5 * For more information regarding TPE, see https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/ Medicare-FFS-Compliance-Programs/Medical-Review/Targeted-Probe-and-EducateTPE.html u Encompass Health reserves pre-payment claim denials as a reduction of net operating revenues upon notice from a MAC a claim is under review. uBackground Ÿ For several years prior to 2018, under programs designated as “widespread probes,” certain Medicare Administrative Contractors (“MACs”) conducted pre-payment claim reviews and denied payment for certain diagnosis codes. Ÿ Since 2018, CMS has replaced the “widespread probes” with the Targeted Probe and Educate (“TPE”) initiative.* Ÿ Encompass Health appeals most denials. – MACs identify medical documentation issues as a leading basis for denials. – Encompass Health’s investment in clinical information systems and its medical services department has further improved its documentation and reduced technical denials.

Encompass Health 25 * This chart does not include ~$381 of finance lease obligations or ~$49 of other notes payable. See the debt schedule on page 26 Debt maturity profile - face value 2022 2023 2024 2024 2025 2026 2027 2028 2029 2030 2031 $350 Senior Notes 5.75% ($ in millions) Revolver capacity $235 Term Loans $800 Senior Notes 4.75% $800 Senior Notes 4.5% Revolver As of March 31, 2022*) $658 Available $305 Drawn + $37 reserved for LCs Callable Callable beginning February 2025Callable beginning February 2023 $400 Senior Notes 4.625% Callable beginning April 2026 During Q1 2022, the Company redeemed its outstanding Senior Notes due 2023 for $100M using its revolver.

Encompass Health 26 Debt schedule Change in March 31, December 31, Debt vs. ($ in millions) 2022 2021 YE 2021 Advances under $1 billion revolving credit facility, November 2024 - LIBOR +150bps $ 305.0 $ 200.0 $ 105.0 Term loan facility, November 2024 - LIBOR +150bps 235.3 238.5 (3.2) Bonds Payable: 5.125% Senior Notes due 2023(1)(6) — 99.6 (99.6) 5.75% Senior Notes due 2025 347.2 347.0 0.2 4.50% Senior Notes due 2028 779.5 786.8 (7.3) 4.75% Senior Notes due 2030 777.2 784.7 (7.5) 4.625% Senior Notes due 2031 389.9 393.7 (3.8) Other notes payable 49.0 49.6 (0.6) Finance lease obligations 381.0 386.8 (5.8) Long-term debt $ 3,264.1 $ 3,286.7 $ (22.6) Debt to Adjusted EBITDA 3.2 x 3.2 x Leverage net of cash on balance sheet 3.1 x 3.1 x Reconciliations to GAAP provided on pages 36-42 Refer to pages 43-44 for end notes.

Encompass Health 27 -10.0 0.0 10.0 20.0 * Includes consolidated inpatient rehabilitation hospitals classified as same store during each period Refer to pages 43-44 for end notes. New-store/same-store growth Inpatient Rehabilitation Yuma, AZ (51 beds)(7) Boise, ID (40 beds) Katy, TX (40 beds) North Tampa, FL (50 beds) Cumming, GA (50 beds) Shreveport, LA (40 beds) Waco, TX (40 beds) Greenville, SC (40 beds) Pensacola, FL (40 beds) Henry County, GA (50 beds)Lubbock, TX (40 beds) Discharges Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 New store 1.5% 2.4% 2.0% 2.3% 2.1% 1.3% 0.9% 1.0% 1.8% 2.0% 3.6% 3.8% Same store* 2.2% 3.1% 3.2% 2.4% (12.8)% (2.8)% (3.8)% (2.2)% 16.9% 6.7% 6.0% 3.8% Total by quarter 3.7% 5.5% 5.2% 4.7% (10.7)% (1.5)% (2.9)% (1.2)% 18.7% 8.7% 9.6% 7.6% Total by year 3.9% (2.6)% 8.7% Same-store year* 1.8% (4.4)% 6.2% Same-store year UDS(8) 1.3% (3.2)% 2.3% Murrieta, CA (50 beds) Sioux Falls, SD (40 beds) Coralville, IA (40 beds) Beginning in mid-March 2020, volume growth was impacted by COVID-19. Toledo, OH (40 beds) San Angelo, TX (40 beds) Shiloh, IL (40 beds) St. Augustine, FL (40 beds) Libertyville, IL (60 beds)

Encompass Health 28 -20.0 -10.0 0.0 10.0 20.0 30.0 New-store/same-store growth Home Health Total admissions Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 New store 2.5% 13.7% 12.6% 13.1% 10.0% 1.1% 1.3% 0.1% 0.9% 1.8% 2.3% 4.0% Same store* 9.3% 10.2% 6.5% 1.2% (14.1)% (6.8)% (5.3)% (3.8)% 13.8% (2.7)% 2.4% 0.9% Total by quarter 11.9% 23.9% 19.0% 14.3% (4.0)% (5.7)% (4.0)% (3.7)% 14.7% (0.9)% 4.7% 4.9% Total by year 16.9% (0.1)% 3.3% Same-store year* 8.1% (5.9)% 1.9% u In 2019, the Company acquired or opened 27 home health locations. u In 2020, the Company acquired or opened two home health locations and consolidated one former equity method location(9). u In 2021, the Company acquired 11 home health locations, merged one location and consolidated one former equity method location(10). u In 2022, the Company acquired one home health location. Acquired Frontier Home Health & Hospice (9 home health locations in 5 states) in June 2021 Acquired Alacare Home Health & Hospice (23 home health locations in Alabama) in July 2019 * Includes consolidated home health agencies classified as same-store during each period Refer to pages 43-44 for end notes. Beginning in mid-March 2020, volume growth was impacted by COVID-19.

Encompass Health 29 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 -20.0 -10.0 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 * Includes consolidated hospice agencies classified as same-store during each period New-store/same-store growth Hospice Admissions Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 New store 15.7% 34.6% 31.1% 30.9% 30.6% 0.5% 0.7% 0.1% 5.3% 11.3% 10.8% 12.4% Same store* 13.6% 5.8% 10.1% (5.3)% 6.7% 15.8% 16.1% 11.4% (1.9)% (14.0)% (14.5)% (14.9)% Total by quarter 29.3% 40.4% 41.2% 25.6% 37.3% 16.3% 16.8% 11.5% 3.4% (2.7)% (3.7)% (2.5)% Total by year 39.8% 23.2% 1.8% Same-store year* 12.2% 8.1% (5.3)% u In 2019, the Company acquired or opened 25 hospice locations. u In 2020, the Company opened one hospice location. u In 2021, the Company acquired or opened 14 hospice locations. u In 2022, the Company acquired or opened three hospice locations. Acquired Frontier Home Health & Hospice (11 hospice locations in 5 states) in June 2021 Acquired Alacare Home Health & Hospice (23 hospice locations in Alabama) in July 2019

Encompass Health 30 Payment sources (percent of revenues) Inpatient Rehabilitation Segment Home Health and Hospice Segment Consolidated Q1 Q1 Q1 Full Year 2022 2021 2022 2021 2022 2021 2021 Medicare 65.1 % 63.9 % 79.2 % 82.7 % 67.9 % 68.1 % 68.2 % Medicare Advantage 14.7 % 16.5 % 12.6 % 10.4 % 14.3 % 15.1 % 14.2 % Managed care 12.4 % 11.7 % 6.9 % 5.3 % 11.3 % 10.3 % 10.7 % Medicaid 3.9 % 4.1 % 1.3 % 1.4 % 3.4 % 3.5 % 3.5 % Other third-party payors 1.0 % 1.3 % — % — % 0.8 % 1.0 % 0.9 % Workers’ compensation 0.6 % 0.6 % — % — % 0.5 % 0.5 % 0.5 % Patients 0.5 % 0.5 % — % 0.1 % 0.4 % 0.4 % 0.4 % Other income 1.8 % 1.4 % — % 0.1 % 1.4 % 1.1 % 1.6 % Total 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 %

Encompass Health 31 Inpatient rehabilitation operational metrics Q1 Q4 Q3 Q2 Q1 Full Year 2022 2021 2021 2021 2021 2021 ($ in millions) Net patient revenue-inpatient $ 1,036.2 $ 1,015.2 $ 983.7 $ 976.9 $ 942.3 $ 3,918.1 Net patient revenue-outpatient and other revenues 23.1 27.4 27.2 24.7 17.6 96.9 Net operating revenues $ 1,059.3 $ 1,042.6 $ 1,010.9 $ 1,001.6 $ 959.9 $ 4,015.0 (actual amounts) Discharges(11) 50,771 50,977 49,983 49,492 47,187 197,639 Net patient revenue per discharge $ 20,409 $ 19,915 $ 19,681 $ 19,739 $ 19,969 $ 19,825 Outpatient visits 35,229 37,952 38,904 44,020 40,194 161,070 Average length of stay 13.0 12.8 12.8 12.7 13.0 12.8 Occupancy % 73.1 % 71.5 % 70.6 % 71.1 % 71.4 % 70.0 % # of licensed beds 10,028 9,924 9,846 9,701 9,560 9,924 Occupied beds 7,330 7,096 6,951 6,897 6,826 6,947 Full-time equivalents (FTEs)(12) 23,313 23,364 23,054 22,535 22,383 22,834 Contract labor 706 516 383 318 221 359 Total FTE and contract labor 24,019 23,880 23,437 22,853 22,604 23,193 EPOB(13) 3.28 3.37 3.37 3.31 3.31 3.34 Refer to pages 43-44 for end notes.

Encompass Health 32 Home health and hospice operational metrics Q1 Q4 Q3 Q2 Q1 Full Year 2022 2021 2021 2021 2021 2021 ($ in millions) Net home health revenue $ 224.9 $ 224.0 $ 221.1 $ 232.3 $ 219.9 $ 897.3 Net hospice revenue 49.4 52.1 52.8 53.8 50.6 209.3 Net operating revenues $ 274.3 $ 276.1 $ 273.9 $ 286.1 $ 270.5 $ 1,106.6 Home Health: (actual amounts) Total admissions(14) 53,309 50,817 48,412 50,598 50,799 200,626 Episodic admissions(14) 38,971 37,908 37,577 39,657 40,215 155,357 Total recertifications 31,787 32,621 32,942 33,794 31,902 131,259 Episodic recertifications 25,808 27,273 27,742 28,296 28,083 111,394 Episodes 63,111 64,242 66,065 67,839 66,435 264,581 Average revenue per episode $ 3,037 $ 3,010 $ 2,916 $ 2,968 $ 2,923 $ 2,954 Episodic visits per episode 15.2 15.1 15.0 15.6 15.8 15.4 Total visits 1,228,084 1,219,906 1,213,370 1,297,350 1,239,073 4,969,699 Cost per visit $ 83 $ 83 $ 82 $ 76 $ 77 $ 79 Hospice: Admissions(15) 3,246 3,223 3,262 3,298 3,330 13,113 Patient days 319,834 334,011 352,691 351,878 334,400 1,372,980 Average daily census 3,554 3,631 3,834 3,867 3,716 3,762 Revenue per day $ 154 $ 156 $ 150 $ 153 $ 151 $ 152 Refer to pages 43-44 for end notes.

Encompass Health 33 Share information Weighted Average for the Period Q1 Full Year (in millions) 2022 2021 2021 2020 2019 Basic shares outstanding 99.2 99.0 99.0 98.6 98.0 Restricted stock awards, dilutive stock options, restricted stock units, and common stock warrants 1.0 1.2 1.2 1.2 1.4 Diluted shares outstanding 100.2 100.2 100.2 99.8 99.4 End of Period Q1 Full Year (in millions) 2022 2021 2021 2020 2019 Basic shares outstanding 99.8 99.6 99.5 99.4 98.6

Encompass Health 34 Segment operating results Q1 2022 Q1 2021 ($ in millions) IRF Home Health and Hospice Reclasses Consolidated IRF Home Health and Hospice Reclasses Consolidated Net operating revenues $ 1,059.3 $ 274.3 $ — $ 1,333.6 $ 959.9 $ 270.5 $ — $ 1,230.4 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (587.4) — (188.6) (776.0) (501.9) — (185.3) (687.2) Other operating expenses(a) (158.3) — (23.2) (181.5) (140.0) — (22.4) (162.4) Supplies (49.8) — (6.3) (56.1) (45.2) — (6.7) (51.9) Occupancy costs (15.4) — (5.5) (20.9) (15.1) — (5.1) (20.2) Home Health and Hospice: Cost of services (excluding depreciation and amortization) — (124.4) 124.4 — — (118.1) 118.1 — Support and overhead costs — (99.2) 99.2 — — (101.4) 101.4 — (810.9) (223.6) — (1,034.5) (702.2) (219.5) — (921.7) Other (expense) income(b) (1.1) — — (1.1) 1.5 — — 1.5 Equity in net income of nonconsolidated affiliates 0.9 — — 0.9 0.8 0.2 — 1.0 Noncontrolling interests (22.0) (0.6) — (22.6) (25.1) (0.4) — (25.5) Segment Adjusted EBITDA $ 226.2 $ 50.1 $ — 276.3 $ 234.9 $ 50.8 $ — 285.7 General and administrative expenses(c)(d) (31.3) (34.9) Adjusted EBITDA $ 245.0 $ 250.8 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss (gain) on disposal or impairment of assets $ 0.7 $ (0.1) $ — $ 0.6 $ — $ (0.1) $ — $ (0.1) (b) Change in fair market value of equity securities $ 2.5 $ — $ — $ 2.5 $ 0.1 $ — $ — $ 0.1 (c) Stock-based compensation $ — $ — $ — $ 7.5 $ — $ — $ — $ 2.8 (d) Costs associated with the strategic alternatives review $ — $ — $ — $ 9.6 $ — $ — $ — $ 0.9 Reconciliations to GAAP provided on pages 36-42

Encompass Health 35 Segment operating results Year Ended December 31, 2021 ($ in millions) IRF Home Health and Hospice Reclasses Consolidated Net operating revenues $ 4,015.0 $ 1,106.6 $ — $ 5,121.6 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (2,127.3) — (759.2) (2,886.5) Other operating expenses(a) (594.8) — (90.0) (684.8) Supplies (184.2) — (25.1) (209.3) Occupancy costs (59.0) — (21.2) (80.2) Home Health and Hospice: Cost of services (excluding depreciation and amortization) — (489.3) 489.3 — Support and overhead costs — (406.2) 406.2 — (2,965.3) (895.5) — (3,860.8) Other income(b)(c) 6.9 1.6 — 8.5 Equity in net income of nonconsolidated affiliates 3.4 0.6 — 4.0 Noncontrolling interests (103.2) (1.8) — (105.0) Segment Adjusted EBITDA $ 956.8 $ 211.5 $ — 1,168.3 General and administrative expenses(d)(e)(f) (140.3) Adjusted EBITDA $ 1,028.0 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss (gain) on disposal or impairment of assets $ 1.2 $ (0.8) $ — $ 0.4 (b) Change in fair market value of equity securities $ (0.6) $ — $ — $ (0.6) (c) Gain on consolidation of former equity method location(10) $ — $ (3.2) $ — $ (3.2) (d) Stock-based compensation $ — $ — $ — $ 32.8 (e) Costs associated with the strategic alternatives review $ — $ — $ — $ 22.9 (f) Costs associated with the Frontier acquisition $ — $ — $ — $ 1.3 Reconciliations to GAAP provided on pages 36-42 Refer to pages 43-44 for end notes.

Encompass Health 36 Reconciliation of net income to Adjusted EBITDA(4) 2022 Q1 ($ in millions, except per share data) Total Per Share Net Income $ 110.1 Net income attributable to noncontrolling interests (22.6) Income from continuing operations attributable to Encompass Health* 87.5 $ 0.87 Provision for income tax expense 31.2 Interest expense and amortization of debt discounts and fees 39.6 Depreciation and amortization 66.2 Loss on early extinguishment of debt(1) 0.3 Loss on disposal or impairment of assets 0.6 Stock-based compensation 7.5 Costs associated with the strategic alternatives review 9.6 Change in fair market value of equity securities 2.5 Adjusted EBITDA $ 245.0 Weighted average common shares outstanding: Basic 99.2 Diluted 100.2 * Per share amounts for each period presented are based on diluted weighted-average shares outstanding. Refer to pages 43-44 for end notes.

Encompass Health 37 Reconciliation of net income to Adjusted EBITDA(4) 2021 Q1 Q2 Q3 Q4 Full Year ($ in millions, except per share data) Total Per Share Total Per Share Total Per Share Total Per Share Total Per Share Net Income $ 132.8 $ 142.0 $ 126.7 $ 115.7 $ 517.2 Loss from disc ops, net of tax, attributable to Encompass Health — 0.3 0.1 — 0.4 Net income attributable to noncontrolling interests (25.5) (28.7) (26.7) (24.1) (105.0) Income from continuing operations attributable to Encompass Health* 107.3 $ 1.07 113.6 $ 1.13 100.1 $ 1.00 91.6 $ 0.91 412.6 $ 4.11 Provision for income tax expense 34.5 39.5 34.1 31.5 139.6 Interest expense and amortization of debt discounts and fees 42.8 41.8 39.9 40.1 164.6 Depreciation and amortization 62.5 63.4 64.9 65.8 256.6 Loss on early extinguishment of debt(6) — 1.0 — — 1.0 (Gain) loss on disposal or impairment of assets (0.1) 2.9 (5.2) 2.8 0.4 Stock-based compensation 2.8 12.0 6.9 11.1 32.8 Costs associated with the strategic alternatives review 0.9 4.1 4.6 13.3 22.9 Costs associated with the Frontier acquisition — 1.3 — — 1.3 Gain on consolidation of former equity method location(10) — — — (3.2) (3.2) Change in fair market value of equity securities 0.1 (0.7) 0.3 (0.3) (0.6) Adjusted EBITDA $ 250.8 $ 278.9 $ 245.6 $ 252.7 $ 1,028.0 Weighted average common shares outstanding: Basic 99.0 99.0 99.0 99.0 99.0 Diluted 100.2 100.2 100.2 100.2 100.2 * Per share amounts for each period presented are based on diluted weighted-average shares outstanding. Refer to pages 43-44 for end notes.

Encompass Health 38 Net cash provided by operating activities reconciled to Adjusted EBITDA(4) Q1 Full Year ($ in millions) 2022 2021 2021 Net cash provided by operating activities $ 218.9 $ 158.5 $ 715.8 Interest expense and amortization of debt discounts and fees 39.6 42.8 164.6 Equity in net income of nonconsolidated affiliates 0.9 1.0 4.0 Net income attributable to noncontrolling interests in continuing operations (22.6) (25.5) (105.0) Amortization of debt-related items (2.3) (2.0) (7.8) Distributions from nonconsolidated affiliates (1.0) (1.0) (2.9) Current portion of income tax expense 29.2 25.8 111.8 Change in assets and liabilities (25.3) 50.3 118.0 Cash used in operating activities of discontinued operations 0.1 — 0.5 Costs associated with the strategic alternatives review 9.6 0.9 22.9 Costs associated with the Frontier acquisition — — 1.3 Change in fair market value of equity securities 2.5 0.1 (0.6) Other (4.6) (0.1) 5.4 Adjusted EBITDA $ 245.0 $ 250.8 $ 1,028.0 Refer to pages 43-44 for end notes.

Encompass Health 39 Reconciliation of segment Adjusted EBITDA to income from continuing operations before income tax expense Three Months Ended Year Ended March 31, December 31, 2022 2021 2021 ($ in millions) Total segment Adjusted EBITDA $ 276.3 $ 285.7 $ 1,168.3 General and administrative expenses (48.4) (38.6) (197.3) Depreciation and amortization (66.2) (62.5) (256.6) (Loss) gain on disposal or impairment of assets (0.6) 0.1 (0.4) Loss on early extinguishment of debt(1)(6) (0.3) — (1.0) Interest expense and amortization of debt discounts and fees (39.6) (42.8) (164.6) Net income attributable to noncontrolling interests 22.6 25.5 105.0 Change in fair market value of equity securities (2.5) (0.1) 0.6 Gain on consolidation of former equity method location(10) — — 3.2 Income from continuing operations before income tax expense $ 141.3 $ 167.3 $ 657.2 Refer to pages 43-44 for end notes.

Encompass Health 40 Reconciliation of net cash provided by operating activities to adjusted free cash flow(3) Q1 Full Year ($ in millions) 2022 2021 2021 Net cash provided by operating activities $ 218.9 $ 158.5 $ 715.8 Impact of discontinued operations 0.1 — 0.5 Net cash provided by operating activities of continuing operations 219.0 158.5 716.3 Capital expenditures for maintenance (34.5) (23.3) (138.8) Distributions paid to noncontrolling interests of consolidated affiliates (21.3) (27.8) (102.9) Items not indicative of ongoing operating performance: Transaction costs and related assumed liabilities 2.7 — 24.2 Adjusted free cash flow $ 165.9 $ 107.4 $ 498.8 Cash dividends on common stock $ 28.5 $ 29.1 $ 112.4 Refer to pages 43-44 for end notes.

Encompass Health 41 Adjusted EPS(2) - Q1 2022 For the Three Months Ended March 31, 2022 Adjustments As Reported Loss on Early Exting. of Debt Income Tax Adjustments Costs Associated with the Strategic Alternatives Review Change in Fair Market Value of Equity Securities As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 245.0 $ — $ — $ — $ — $ 245.0 Depreciation and amortization (66.2) — — — — (66.2) Interest expense and amortization of debt discounts and fees (39.6) — — — — (39.6) Stock-based compensation (7.5) — — — — (7.5) Loss on disposal or impairment of assets (0.6) — — — — (0.6) Loss on early extinguishment of debt(1) (0.3) 0.3 — — — — Costs associated with the strategic alternatives review (9.6) — — 9.6 — — Change in fair market value of equity securities (2.5) — — — 2.5 — Income from continuing operations before income tax expense 118.7 0.3 — 9.6 2.5 131.1 Provision for income tax expense (31.2) (0.1) 0.2 (2.5) (0.6) (34.2) Income from continuing operations attributable to Encompass Health $ 87.5 $ 0.2 $ 0.2 $ 7.1 $ 1.9 $ 96.9 Diluted earnings per share from continuing operations* $ 0.87 $ — $ — $ 0.07 $ 0.02 $ 0.97 Diluted shares used in calculation 100.2 * Adjusted EPS may not sum across due to rounding. Refer to pages 43-44 for end notes.

Encompass Health 42 For the Three Months Ended March 31, 2021 Adjustments As Reported Income Tax Adjustments Costs Associated with the Strategic Alternatives Review Change in Fair Market Value of Equity Securities As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 250.8 $ — $ — $ — $ 250.8 Depreciation and amortization (62.5) — — — (62.5) Interest expense and amortization of debt discounts and fees (42.8) — — — (42.8) Stock-based compensation (2.8) — — — (2.8) Gain on disposal or impairment of assets 0.1 — — — 0.1 Costs associated with the strategic alternatives review (0.9) — 0.9 — — Change in fair market value of equity securities (0.1) — — 0.1 — Income from continuing operations before income tax expense 141.8 — 0.9 0.1 142.8 Provision for income tax expense (34.5) (3.3) (0.2) — (38.0) Income from continuing operations attributable to Encompass Health $ 107.3 $ (3.3) $ 0.7 $ 0.1 $ 104.8 Diluted earnings per share from continuing operations* $ 1.07 $ (0.03) $ 0.01 $ — $ 1.05 Diluted shares used in calculation 100.2 Adjusted EPS(2) - Q1 2021 * Adjusted EPS may not sum across due to rounding. Refer to pages 43-44 for end notes.

Encompass Health 43 End notes (1) In the first quarter of 2022, the Company redeemed the remaining $100 million of its 5.125% Senior Notes due 2023. The redemption was completed at 100% of par using drawings under the Company’s revolving credit facility. As a result of the redemption, the Company recorded a $0.3 million loss on early extinguishment of debt in the first quarter of 2022. (2) The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”), which is a non-GAAP measure. The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements, professional fees - accounting, tax, and legal, mark-to-market adjustments for stock appreciation rights, gains or losses related to hedging and equity instruments, loss on early extinguishment of debt, adjustments to its income tax provision (such as valuation allowance adjustments, settlements of income tax claims and windfall tax benefits), items related to corporate and facility restructurings, and certain other items deemed to be non-indicative of ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company's ongoing operating performance. Accordingly, they can complicate comparisons of the Company's results of operations across periods and comparisons of the Company's results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies.* (3) Definition of adjusted free cash flow, which is a non-GAAP measure, is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, dividends paid on preferred stock, distributions to noncontrolling interests, and certain other items deemed to be non- indicative of ongoing operating performance. Common stock dividends are not included in the calculation of adjusted free cash flow. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. (4) Adjusted EBITDA is a non-GAAP financial measure. The Company’s leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP measure. Management and some members of the investment community utilize Adjusted EBITDA as a financial measure and the leverage ratio as a liquidity measure on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating Adjusted EBITDA, the reader should be aware that in the future the Company may incur expenses similar to the adjustments set forth. (5) On Oct. 28, 2013, the Company announced its board of directors authorized the repurchase of up to $200 million of its common stock. On Feb. 14, 2014, the Company's board approved an increase in this common stock repurchase authorization from $200 million to $250 million. As of June 30, 2018, the remaining repurchase authorization was approximately $58 million. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to $250 million. As of March 31, 2022, the remaining repurchase authorization was approximately $198 million. (6) In the second quarter of 2021, the Company redeemed a total of $200 million of 5.125% Senior Notes due 2023 ($100 million in April and $100 million in June). The redemptions were completed at 100% of par using cash on hand and drawings under the Company’s revolving credit facility. As a result of the redemptions, the Company recorded a $1.0 million loss on early extinguishment of debt in the second quarter of 2021. (7) As a result of negotiations with our partner to amend the joint venture agreement related to Yuma Rehabilitation Hospital, the accounting for this hospital changed from the equity method of accounting to a consolidated entity effective July 1, 2019. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. As a result of our consolidation of this hospital and the remeasurement of our previously held equity interest at fair value, we recorded a $19.2 million gain as part of other income in the third quarter of 2019. (8) Data provided by Uniform Data System for Medical Rehabilitation, a division of UB Foundation Activities, Inc., a data gathering and analysis organization for the rehabilitation industry; represents ~80% of industry, including Encompass Health inpatient rehabilitation sites. (9) As a result of an amendment to the joint venture agreement related to our home health location in Treasure Coast, Florida, the accounting for this agency changed from the equity method of accounting to a consolidated entity effective January 1, 2020. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. As a result of our consolidation of this agency and the remeasurement of our previously held equity interest at fair value, we recorded a $2.2 million gain as part of other income in the first quarter of 2020. * Reconciliations to GAAP provided on pages 36-42.

Encompass Health 44 End notes, continued (10) As a result of an amendment to the joint venture agreement related to our home health location in Boynton Beach, Florida, the accounting for this agency changed from the equity method of accounting to a consolidated entity effective December 1, 2021. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. As a result of our consolidation of this agency and the remeasurement of our previously held equity interest at fair value, we recorded a $3.2 million gain as part of other income in the fourth quarter of 2021. (11) Represents discharges from 147 consolidated hospitals in Q1 2022; 145 consolidated hospitals in Q4 2021; 144 consolidated hospitals in Q3 2021; 140 consolidated hospitals in Q2 2021; and 138 consolidated hospitals in Q1 2021. (12) Full-time equivalents included in the table represent Encompass Health employees who participate in or support the operations of our hospitals and include an estimate of full-time equivalents related to contract labor. (13) Employees per occupied bed, or “EPOB,” is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company’s occupancy percentage. (14) Represents home health admissions from 252 consolidated locations in Q1 2022; 251 consolidated locations in Q4 2021; 248 consolidated locations in Q3 2021 and Q2 2021; and 240 consolidated locations in Q1 2021. (15) Represents hospice admissions from 99 locations in Q1 2022; 96 locations in Q4 2021; 95 locations in Q3 2021; 94 locations in Q2 2021; and 82 locations in Q1 2021.